153 related articles for article (PubMed ID: 27141891)
1. Functional differences in hepatitis C virus nonstructural (NS) 3/4A- and 5A-specific T cell responses.
Holmström F; Chen M; Balasiddaiah A; Sällberg M; Ahlén G; Frelin L
Sci Rep; 2016 May; 6():24991. PubMed ID: 27141891
[TBL] [Abstract][Full Text] [Related]
2. A non-human hepadnaviral adjuvant for hepatitis C virus-based genetic vaccines.
Levander S; Sällberg M; Ahlén G; Frelin L
Vaccine; 2016 May; 34(25):2821-33. PubMed ID: 27109565
[TBL] [Abstract][Full Text] [Related]
3. Cleavage of the T cell protein tyrosine phosphatase by the hepatitis C virus nonstructural 3/4A protease induces a Th1 to Th2 shift reversible by ribavirin therapy.
Brenndörfer ED; Brass A; Karthe J; Ahlén G; Bode JG; Sällberg M
J Immunol; 2014 Feb; 192(4):1671-80. PubMed ID: 24442435
[TBL] [Abstract][Full Text] [Related]
4. A synthetic codon-optimized hepatitis C virus nonstructural 5A DNA vaccine primes polyfunctional CD8+ T cell responses in wild-type and NS5A-transgenic mice.
Holmström F; Pasetto A; Nähr V; Brass A; Kriegs M; Hildt E; Broderick KE; Chen M; Ahlén G; Frelin L
J Immunol; 2013 Feb; 190(3):1113-24. PubMed ID: 23284053
[TBL] [Abstract][Full Text] [Related]
5. Cleavage of the IPS-1/Cardif/MAVS/VISA does not inhibit T cell-mediated elimination of hepatitis C virus non-structural 3/4A-expressing hepatocytes.
Ahlén G; Derk E; Weiland M; Jiao J; Rahbin N; Aleman S; Peterson DL; Pokrovskaja K; Grandér D; Frelin L; Sällberg M
Gut; 2009 Apr; 58(4):560-9. PubMed ID: 18689426
[TBL] [Abstract][Full Text] [Related]
6. Strong HCV NS3/4a, NS4b, NS5a, NS5b-specific cellular immune responses induced in Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine.
Latimer B; Toporovski R; Yan J; Pankhong P; Morrow MP; Khan AS; Sardesai NY; Welles SL; Jacobson JM; Weiner DB; Kutzler MA
Hum Vaccin Immunother; 2014; 10(8):2357-65. PubMed ID: 25424943
[TBL] [Abstract][Full Text] [Related]
7. In vivo electroporation enhances the immunogenicity of hepatitis C virus nonstructural 3/4A DNA by increased local DNA uptake, protein expression, inflammation, and infiltration of CD3+ T cells.
Ahlén G; Söderholm J; Tjelle T; Kjeken R; Frelin L; Höglund U; Blomberg P; Fons M; Mathiesen I; Sällberg M
J Immunol; 2007 Oct; 179(7):4741-53. PubMed ID: 17878373
[TBL] [Abstract][Full Text] [Related]
8. Oral Combination Vaccine, Comprising Bifidobacterium Displaying Hepatitis C Virus Nonstructural Protein 3 and Interferon-α, Induces Strong Cellular Immunity Specific to Nonstructural Protein 3 in Mice.
Kitagawa K; Omoto C; Oda T; Araki A; Saito H; Shigemura K; Katayama T; Hotta H; Shirakawa T
Viral Immunol; 2017 Apr; 30(3):196-203. PubMed ID: 28112593
[TBL] [Abstract][Full Text] [Related]
9. Induction of cell-mediated immune responses in mice by DNA vaccines that express hepatitis C virus NS3 mutants lacking serine protease and NTPase/RNA helicase activities.
Ratnoglik SL; Jiang DP; Aoki C; Sudarmono P; Shoji I; Deng L; Hotta H
PLoS One; 2014; 9(6):e98877. PubMed ID: 24901478
[TBL] [Abstract][Full Text] [Related]
10. Heterologous T cells can help restore function in dysfunctional hepatitis C virus nonstructural 3/4A-specific T cells during therapeutic vaccination.
Chen A; Ahlén G; Brenndörfer ED; Brass A; Holmström F; Chen M; Söderholm J; Milich DR; Frelin L; Sällberg M
J Immunol; 2011 May; 186(9):5107-18. PubMed ID: 21430225
[TBL] [Abstract][Full Text] [Related]
11. Broadening CD4
Filskov J; Mikkelsen M; Hansen PR; Christensen JP; Thomsen AR; Andersen P; Bukh J; Agger EM
J Virol; 2017 Jul; 91(14):. PubMed ID: 28446674
[TBL] [Abstract][Full Text] [Related]
12. Sequential Phosphorylation of the Hepatitis C Virus NS5A Protein Depends on NS3-Mediated Autocleavage between NS3 and NS4A.
Chiang CH; Lai YL; Huang YN; Yu CC; Lu CC; Yu GY; Yu MJ
J Virol; 2020 Sep; 94(19):. PubMed ID: 32699091
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C virus non-structural 3/4A protein interferes with intrahepatic interferon-γ production.
Brenndörfer ED; Brass A; Söderholm J; Frelin L; Aleman S; Bode JG; Sällberg M
Gut; 2012 Apr; 61(4):589-96. PubMed ID: 21813471
[TBL] [Abstract][Full Text] [Related]
14. The hepatitis C virus non-structural NS5A protein impairs both the innate and adaptive hepatic immune response in vivo.
Kriegs M; Bürckstümmer T; Himmelsbach K; Bruns M; Frelin L; Ahlén G; Sällberg M; Hildt E
J Biol Chem; 2009 Oct; 284(41):28343-28351. PubMed ID: 19674968
[TBL] [Abstract][Full Text] [Related]
15. Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors.
Li YP; Ramirez S; Humes D; Jensen SB; Gottwein JM; Bukh J
Gastroenterology; 2014 Mar; 146(3):812-821.e4. PubMed ID: 24262279
[TBL] [Abstract][Full Text] [Related]
16. In vivo clearance of hepatitis C virus nonstructural 3/4A-expressing hepatocytes by DNA vaccine-primed cytotoxic T lymphocytes.
Ahlen G; Nystrom J; Pult I; Frelin L; Hultgren C; Sallberg M
J Infect Dis; 2005 Dec; 192(12):2112-6. PubMed ID: 16288375
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C virus NS2 and NS3/4A proteins are potent inhibitors of host cell cytokine/chemokine gene expression.
Kaukinen P; Sillanpää M; Kotenko S; Lin R; Hiscott J; Melén K; Julkunen I
Virol J; 2006 Sep; 3():66. PubMed ID: 16945160
[TBL] [Abstract][Full Text] [Related]
18. Identification of drug resistance and immune-driven variations in hepatitis C virus (HCV) NS3/4A, NS5A and NS5B regions reveals a new approach toward personalized medicine.
Ikram A; Obaid A; Awan FM; Hanif R; Naz A; Paracha RZ; Ali A; Janjua HA
Antiviral Res; 2017 Jan; 137():112-124. PubMed ID: 27984060
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of antiviral effect of type I, II, and III interferons on direct-acting antiviral-resistant hepatitis C virus.
Hamana A; Takahashi Y; Uchida T; Nishikawa M; Imamura M; Chayama K; Takakura Y
Antiviral Res; 2017 Oct; 146():130-138. PubMed ID: 28864074
[TBL] [Abstract][Full Text] [Related]
20. Low dose and gene gun immunization with a hepatitis C virus nonstructural (NS) 3 DNA-based vaccine containing NS4A inhibit NS3/4A-expressing tumors in vivo.
Frelin L; Alheim M; Chen A; Söderholm J; Rozell B; Barnfield C; Liljeström P; Sällberg M
Gene Ther; 2003 Apr; 10(8):686-99. PubMed ID: 12692597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
